Commercial Diligence Before Scale: The Pricing Questions That Must Be Answered

There is a predictable pattern in private equity (PE) deal failures. It does not start at the exit. It starts in the IC memo, in the section labeled "commercial due diligence," where the analysis confirms the market is large, the product is competitive, and there is "significant pricing upside at renewal."

That finding is not commercial diligence. It is commercial reassurance.

The difference matters when you are 30 months into a hold, net revenue retention (NRR) is running 8 points below model, and your exit timeline has just extended by a year.

What's at Stake

The cost of incomplete commercial due diligence does not appear on a P&L for 18 to 24 months, which is why it gets repeated. The team that approved the deal has moved on to the next deal. The operating partner is managing the portco. The original CDD findings are buried in a virtual data room.

What surfaces instead is a set of symptoms that look like operational problems. Sales cycles are getting longer. Churn is running above model in a specific customer tier. The pricing initiative that management promised in the 100-day plan has stalled because the sales team is resisting it.

Those are not operational problems. They are commercial architecture problems that were present at close and were not diagnosed because CDD did not test the right hypotheses.

The specific cost in dollar terms is significant. For a portco that entered at $50 million annual recurring revenue (ARR) with a 100 percent NRR assumption, running at 92 percent NRR instead means $4 million of ARR per year that disappears rather than compounds. Over a 36-month hold, that is $12 million of ARR that was in the model and will not be there at exit. At a 6x multiple, that is $72 million of enterprise value.

Every dollar of that gap was visible in the pre-close data. The cohort-level retention data, the discount exception logs, the customer interviews about switching cost: all of it was available. CDD just did not ask for it in the right way.

The Method

Step 1: Identify the three pricing prerequisites your deal thesis requires.

A deal thesis is a set of commercial assumptions. Before CDD begins, write down the three pricing-related assumptions that your entry multiple depends on. Typical examples: "NRR will expand from 103 to 110 percent over the hold as we raise prices at renewal," or "average annual contract value (ACV) will increase from $42,000 to $55,000 as we move upmarket," or "gross retention will hold above 88 percent through a price restructure in year two."

Each of those assumptions is a prerequisite. CDD's job is to either confirm or refute each one before you close.

Step 2: Build data requests and interview questions that test each prerequisite.

For the NRR expansion prerequisite, the data request is not "provide NRR over the last four quarters." It is: "provide cohort NRR by acquisition year and plan tier for the last 36 months, with a breakout of expansion versus contraction, and provide the retention data specifically for any cohort that experienced a price change in the last 24 months."

For the ACV growth prerequisite, the primary research question is: "In your last three contract renewals with accounts in the $40,000 to $60,000 ACV band, what drove the final price? What would have caused those accounts to not renew or to negotiate down?"

The specificity of the question determines the quality of the answer. Generic CDD questions produce generic answers that confirm existing assumptions rather than testing them.

Step 3: Treat ambiguous findings as rejections, not as maybes.

The most dangerous CDD finding is "data is insufficient to assess pricing upside with confidence." That finding usually gets treated as a yellow flag rather than a red one. It should be treated as a rejection of the assumption until positive evidence exists.

If you cannot confirm pricing power before close, you are assuming it. Assumed pricing power that does not materialize is the single largest contributor to underperformance against plan in PE-backed SaaS portfolios.

The Common Mistake

A growth equity fund acquired a B2B data platform at 10x ARR. CDD confirmed that the company was 25 percent below market pricing for comparable data products. The IC memo noted this as upside and the 100-day plan included "pricing review and realignment."

What CDD did not do was test whether customers would absorb the price increase. Customer interviews during diligence focused on feature roadmap and competitive alternatives. No one asked about price sensitivity or switching cost quantification.

In year one of the hold, management raised prices 20 percent on renewal. Gross retention in the affected cohort fell from 90 percent to 82 percent. Net revenue retention, which had been 108 percent, fell to 97 percent. The expansion revenue that had funded the deal thesis disappeared.

The fund's year-two board presentation showed top-line ARR below plan by $3.8 million. The board session was tense. The operating partner was asked to explain how the CDD had missed the pricing sensitivity.

The answer, as it always is in these situations, was that CDD had confirmed price was below market. It had never tested whether customers would stay at market price.

At exit in year four, the company sold at 8x ARR, down from the 12x target MOIC entry model. The fund returned 1.6x gross on a deal that underwrote to 3.4x.

Immediate Steps

If you have a deal in process, write down your three pricing prerequisites today. Not after IC. Today.

Then audit your current data room request list against those prerequisites. For each prerequisite, identify whether you have asked for data that could reject it. If the answer is no for any of the three, add those requests to your data room tracker before the end of this week.

If you are post-close and realizing that CDD did not answer the pricing questions you needed, the same framework applies to your 100-day audit. Start with the pocket price waterfall and the cohort retention data and build your first hypothesis from what you find.

For a structured assessment of pricing health that maps directly to CDD findings, use the FintastIQ Pricing Diagnostic. It is designed to be completed in parallel with standard financial diligence.

To go deeper on how to connect CDD findings to a 100-day value creation plan, see our post on the hypothesis-led approach to pricing in PE value creation.